S11 Ep40: T-DXd Steadily Transforms the NSCLC Treatment Paradigm: With Misako Nagasaka, MD, PhD

In today’s episode, supported by Daiichi Sankyo, we had the pleasure of speaking with Misako Nagasaka, MD, PhD, about the use of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in patients with non–small cell lung cancer (NSCLC). Dr Nagasaka is an associate professor in the Division of Hematology and Oncology and the Division of Medicine at the University of California Irvine School of Medicine. In our exclusive interview, Dr Nagasaka discussed key findings from the phase 2 DESTINY-PanTumor02 (NCT04482309) and DESTINY-Lung01 (NCT03505710) trials that led to the FDA approval of T-DXd for patients with unresectable or metastatic HER2-positive solid tumors, including those with NSCLC; where next-generation sequencing fits into her clinical practice; and the current role of T-DXd in lung cancer management.